Characterization and comparison of GITR expression in solid tumors.

CONCLUSIONS: Human tumor data suggest that NSCLC, RCC, and melanoma should be the tumor subtypes prioritized for anti-GITR therapy development.
PMID: 31358539 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - July 28, 2019 Category: Cancer & Oncology Authors: Vence L, Bucktrout SL, Fernandez Curbelo I, Blando J, Smith BM, Mahne AE, Lin JC, Park T, Pascua E, Chaparro-Riggers J, Subudhi SK, Borin Scutti J, Higa MG, Zhao H, Yadav SS, Maitra A, Wistuba II, Allison JP, Sharma P Tags: Clin Cancer Res Source Type: research